Abbott/Adria Oncology Products
Executive Summary
Abbott will market Adria's entire line of multi-source oncology products, including Adriamycin, Adrucil and Folex, to hospitals, wholesalers, and home health care agencies under an agreement announced Nov. 16. Adria, a division of Erbamont, will continue to sell the products to oncology clinics, physicians offices, and oncology wholesalers. Adria hopes to take advantage of Abbott's large sales force to protect Adriamycin (doxorubicin HCl) from generic competition from Bristol-Myers Squibb's Rubex and Cetus-Ben Venue's Doxorubicin HCl. A press release issued by the two companies calls Abbott the U.S. "market leader in multi-source hospital injectable products." The two companies also announced that they "have agreed to jointly develop drug delivery systems for the reconstitution and delivery of chemotherapeutic agents." Adria indicated that the two companies would work to modify existing Abbott drug delivery systems (especially the ADD-Vantage I.V. system) to suit Adria's oncology products.
You may also be interested in...
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.